BR112016026046A2 - Uso de compostos de tienotriazolodiazepina - Google Patents
Uso de compostos de tienotriazolodiazepinaInfo
- Publication number
- BR112016026046A2 BR112016026046A2 BR112016026046A BR112016026046A BR112016026046A2 BR 112016026046 A2 BR112016026046 A2 BR 112016026046A2 BR 112016026046 A BR112016026046 A BR 112016026046A BR 112016026046 A BR112016026046 A BR 112016026046A BR 112016026046 A2 BR112016026046 A2 BR 112016026046A2
- Authority
- BR
- Brazil
- Prior art keywords
- thienotriazolodiazepine compounds
- thienotriazolodiazepine
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990457P | 2014-05-08 | 2014-05-08 | |
| US201462012048P | 2014-06-13 | 2014-06-13 | |
| US201462080751P | 2014-11-17 | 2014-11-17 | |
| US201462086400P | 2014-12-02 | 2014-12-02 | |
| US201562150044P | 2015-04-20 | 2015-04-20 | |
| PCT/EP2015/060200 WO2015169951A1 (en) | 2014-05-08 | 2015-05-08 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016026046A2 true BR112016026046A2 (pt) | 2017-08-15 |
| BR112016026046A8 BR112016026046A8 (pt) | 2021-07-20 |
Family
ID=53191652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016026046A BR112016026046A8 (pt) | 2014-05-08 | 2015-05-08 | uso de compostos de tienotriazolodiazepina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9968619B2 (pt) |
| EP (1) | EP3139959A1 (pt) |
| JP (1) | JP2017519727A (pt) |
| KR (1) | KR20170002610A (pt) |
| CN (1) | CN106852120A (pt) |
| AU (1) | AU2015257658A1 (pt) |
| BR (1) | BR112016026046A8 (pt) |
| CA (1) | CA2947970A1 (pt) |
| MX (1) | MX2016014574A (pt) |
| RU (1) | RU2016147946A (pt) |
| WO (1) | WO2015169951A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151990A1 (es) | 2013-03-15 | 2016-01-13 | Incyte Corp | Heterociclos triciclicos como inhibidores de la proteina bet |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| CR20160542A (es) | 2014-04-23 | 2017-04-25 | Incyte Corp | 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| CA3220957A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| US20230133761A1 (en) * | 2020-03-12 | 2023-05-04 | Heinrich-Heine-Universität Düsseldorf | Inhibition of fkbp1a for the treatment of triple-negative mammary carcinoma |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
| AU2001264303A1 (en) | 2000-06-16 | 2001-12-24 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| MX2012013255A (es) | 2010-05-14 | 2013-02-27 | Dana Farber Cancer Inst Inc | Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| US20130345145A1 (en) * | 2011-03-10 | 2013-12-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Atip3 and biologically active fragments thereof for use in the treatment of cancer |
| US20140018353A1 (en) | 2012-06-25 | 2014-01-16 | Oncoethix Sa | Method of treating b-cell malignant cancers and t-cell malignant cancers using thienotriazolodiazepine compounds |
| JP2015522025A (ja) * | 2012-06-27 | 2015-08-03 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリＴｈｅ Ｃｕｒａｔｏｒｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｓｓｏｕｒｉ | コレステロール生合成阻害剤によるエストロゲン受容体βの誘発および癌の処置方法 |
| RU2015115634A (ru) | 2012-09-28 | 2016-11-20 | Онкоэтикс Гмбх | Фармацевтический состав, содержащий соединения тиенотриазолодиазепина |
| SI2903616T1 (en) * | 2012-10-04 | 2018-02-28 | Ab Science | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
-
2015
- 2015-05-08 CN CN201580037334.9A patent/CN106852120A/zh active Pending
- 2015-05-08 CA CA2947970A patent/CA2947970A1/en not_active Abandoned
- 2015-05-08 BR BR112016026046A patent/BR112016026046A8/pt not_active IP Right Cessation
- 2015-05-08 MX MX2016014574A patent/MX2016014574A/es unknown
- 2015-05-08 EP EP15723671.2A patent/EP3139959A1/en not_active Withdrawn
- 2015-05-08 US US15/308,525 patent/US9968619B2/en not_active Expired - Fee Related
- 2015-05-08 AU AU2015257658A patent/AU2015257658A1/en not_active Abandoned
- 2015-05-08 WO PCT/EP2015/060200 patent/WO2015169951A1/en active Application Filing
- 2015-05-08 RU RU2016147946A patent/RU2016147946A/ru not_active Application Discontinuation
- 2015-05-08 KR KR1020167034522A patent/KR20170002610A/ko unknown
- 2015-05-08 JP JP2016566962A patent/JP2017519727A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017519727A (ja) | 2017-07-20 |
| CA2947970A1 (en) | 2015-11-12 |
| US9968619B2 (en) | 2018-05-15 |
| RU2016147946A3 (pt) | 2018-12-26 |
| CN106852120A (zh) | 2017-06-13 |
| WO2015169951A1 (en) | 2015-11-12 |
| KR20170002610A (ko) | 2017-01-06 |
| BR112016026046A8 (pt) | 2021-07-20 |
| AU2015257658A1 (en) | 2016-11-10 |
| RU2016147946A (ru) | 2018-06-08 |
| US20170065607A1 (en) | 2017-03-09 |
| MX2016014574A (es) | 2017-02-23 |
| EP3139959A1 (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002055A1 (es) | Uso de compuestos 3-isoxazolidinonas como herbicidas selectivos | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| CL2016002129A1 (es) | Compuestos de azolina | |
| ES2968308T3 (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| DK3040326T3 (da) | Haloolefin-baseret sammensætning | |
| BR112016026046A2 (pt) | Uso de compostos de tienotriazolodiazepina | |
| BR112016020889A2 (pt) | variantes de hppd e métodos de uso | |
| DK3174483T3 (da) | Hyporørkonstruktion | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| FR3024363B1 (fr) | Composition thermogelifiable | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| BR112016030730A2 (pt) | Composto | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| DK3183242T3 (da) | Substituerede bicykliske forbindelser | |
| CL2017000639A1 (es) | Composición | |
| DK3597189T3 (da) | Krystallinske forbindelser | |
| BR112016021620A2 (pt) | compostos e seus métodos de uso | |
| BR112016017925A2 (pt) | Formulação de colagem estabilizada | |
| FR3022129B1 (fr) | Baignoire de puericulture | |
| DK3217964T3 (da) | Sammensætning | |
| BR112016027580A2 (pt) | Formulação de ceritinib | |
| FR3024647B1 (fr) | Transat de puericulture | |
| ES1115580Y (es) | Herramienta de preparacion de pestanas | |
| FR3019552B1 (fr) | Composition filmogene | |
| ES2697898T8 (es) | Compuestos triazólicos tricíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |